Care Pathway Model for Patients with Localized Lung Adenocarcinoma

Lung adenocarcinoma is a common type of lung cancer that arises from the cells that line the lung airways. Having a care pathway model for patients with localized lung adenocarcinoma is an essential step toward improving the quality of care and outcomes for these patients. The care pathway begins with the screening and diagnosis of lung adenocarcinoma. This first step includes imaging tests such as chest X-rays, CT scans, and PET scans, as well as tissue biopsies to confirm the diagnosis. Once a diagnosis is confirmed, the patient is referred to a multidisciplinary team of specialists for treatment planning. The treatment plan is tailored to the individual patient based on factors such as the stage of the cancer, the patient's overall health, and the patient's treatment goals. Treatment options may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination. The care pathway is based on the decision issued by supervised machine learning. The oncologist validates this choice. Based on the diagnosis, the model allows classifying the patient's condition and proposes the appropriate treatment. Developing the machine learning model involves training the model using a large dataset of patient information and clinical outcomes. Once the model is trained, it must be validated using independent datasets and further refined using feedback from clinical experts. Then, it can integrate the software system to help medical staff guide treatment decisions and optimize patient outcomes. After treatment, the care pathway includes regular follow-up visits to monitor the patient's condition and provide supportive care.